Aprocitentan

DRUG5 trials

Sponsors

Idorsia Pharmaceuticals Ltd.

Conditions

Drug Drug InteractionHealthy SubjectsHepatic Impairment

Phase 1

Clinical Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects

CompletedNCT02708004

Idorsia Pharmaceuticals Ltd.Healthy Subjects

Start: 2016-06-01End: 2016-12-01Updated: 2022-11-29

A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects

CompletedNCT02841761

Idorsia Pharmaceuticals Ltd.Healthy Subjects

Start: 2016-07-01End: 2016-10-01Updated: 2022-11-29

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)

CompletedNCT03245229

Idorsia Pharmaceuticals Ltd.Healthy Subjects

Start: 2017-08-10End: 2017-09-18Updated: 2022-11-29

The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

CompletedNCT04252495

Idorsia Pharmaceuticals Ltd.Healthy Subjects, Hepatic Impairment

Start: 2020-06-26End: 2021-05-06Updated: 2022-11-23

A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives

CompletedNCT06799884

Idorsia Pharmaceuticals Ltd.Drug Drug Interaction

Start: 2025-01-18End: 2025-02-21Updated: 2025-03-11

Related Papers

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

Scientific Reports2022-11-0917 citations